Table of Contents Show
The biotechnology sector continues to witness substantial investor interest in breakthrough therapeutic approaches, with Pandorum Technologies emerging as a notable beneficiary. The Bangalore based regenerative medicine company has successfully concluded an $18 million Series B financing round, positioning itself for significant expansion across multiple international markets.
Strategic Investment and Valuation Milestone
Protons Corporate spearheaded the investment round, demonstrating strong institutional confidence in Pandorum’s technological platform and commercial strategy. The funding attracted a diverse consortium of investors, including Galentic Pharma, prominent angel investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family. This broad investor base reflects the compelling value proposition of the company’s exosome based therapeutic approach.
The capital infusion establishes Pandorum’s post money valuation at approximately $91 million, representing substantial growth from previous funding stages. The company has now accumulated roughly $43 million in total capital since inception, providing a robust financial foundation for its ambitious development programs.
Technology Platform and Market Strategy
Founded by entrepreneurs Tuhin Bhowmick and Arun Chandru, Pandorum has developed a specialized focus on programmable tissue regenerative therapies utilizing exosome technology. This innovative approach addresses critical unmet needs in regenerative medicine, offering potential solutions for tissue repair and restoration that conventional treatments cannot adequately address.
The company’s strategic vision extends beyond traditional geographic boundaries. Management has identified the United States, Japan, and Middle Eastern markets as priority expansion territories, recognizing the significant commercial opportunities these regions present for advanced regenerative therapeutics.
Manufacturing Infrastructure and Partnerships
Pandorum has established a globally distributed manufacturing framework designed to support international commercialization efficiently. The company has forged strategic alliances with AGC Biologics to ensure production capabilities across the United States and European markets. Simultaneously, a partnership with Nucelion Therapeutics, a subsidiary of the established vaccine manufacturer Bharat Biotech, will facilitate supply chain operations throughout the Asia-Pacific region.
Capital Deployment and Future Outlook
The Series B proceeds will be strategically allocated across several critical operational areas. Clinical program advancement represents a primary investment priority, enabling the company to progress its therapeutic candidates through regulatory pathways. Manufacturing capacity expansion will support anticipated commercial demand, while regulatory and clinical team strengthening will ensure compliance readiness across multiple jurisdictions.
Despite operating in a pre-revenue stage during the fiscal year 2024, with reported losses of approximately Rs 28.2 crore, Pandorum’s successful capital raise demonstrates investor confidence in the long term commercial potential of its regenerative medicine platform. As the company advances toward clinical milestones and regulatory approvals, stakeholders will monitor progress closely in this rapidly evolving therapeutic domain.
Also Read: Kerala Based Healthcare Startup Preventify Secures ₹2 Crore Pre-Seed Funding Led by PedalStart
